EI
DSGN icon

EAM Investors’s Design Therapeutics DSGN Stock Holding History

EAM Investors’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,949
Closed -$840K – 302
2026
Q1 		$840K Hold
78,949
– – 0.1% 225
2025
Q4 		$741K Buy
+78,949
New +$618K 0.08% 236

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM Investors's DSGN Position: Q2 2026 in Review

EAM Investors sold out of Design Therapeutics (DSGN) in Q2 2026, closing a stake of 78,949 shares — an estimated $840K sold.

EAM Investors first reported a position in DSGN in Q4 2025 and held it in 2 quarters. The position peaked at $840K in Q1 2026. 137 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • EAM Investors reported no remaining Design Therapeutics position as of Q2 2026 after selling out during the quarter.
  • EAM Investors sold 78,949 Design Therapeutics shares in Q2 2026, an estimated $840K.
  • EAM Investors first reported a position in Design Therapeutics in Q4 2025 and held it in 2 quarters.
  • EAM Investors's Design Therapeutics position peaked at $840K in Q1 2026.
  • 137 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.